INTERVIEW

• From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
  February 8, 2021

• Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
  February 2, 2021

• Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
  February 10, 2020

• “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
  January 28, 2020

• Causes of NDMA Contamination Scandal Still under Investigation: NIHS Division of Drugs
  January 27, 2020

• Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
  September 12, 2019

• As Election Campaign Begins, LDP’s Eto Says Debate Needed to Possibly Expand 2% Adjustment Rate for Drug Price Revisions
  July 4, 2019

• As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
  May 8, 2019

• Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
  April 23, 2019

• Nichi-Iko to Leverage Synergies of Integration with Elmed Eisai: Sales Head
  April 22, 2019

• With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
  April 5, 2019

• Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
  April 3, 2019

• Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
  March 29, 2019

• I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief
  March 28, 2019

• With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
  March 26, 2019

• JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
  March 7, 2019

• Interview: Pfizer Japan Looks to Offer High Quality Biosimilars with Go-It-Alone Strategy
  February 2, 2018

• Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO
  January 10, 2018

• Chordia President Confident in Success of “Synthetic Lethality” Drug; Negotiated Directly with Takeda to Establish Startup
  December 7, 2017

• Takeda Eager to Build Life Science Hub in Shonan, Offer Research Environment Akin to US East Coast: Exec Hirate
  October 24, 2017

ページ

• 1
• 2
• Next ›
• 最終 »